Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
|
|
Cocrystal Pharma, Inc. (COCP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/16/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/12/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/24/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/12/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 04/27/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/24/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/06/2023 |
4
| FROST PHILLIP MD ET AL (10% Owner) has filed a Form 4 on Cocrystal Pharma, Inc.|
Txns:
| Bought 1,015,229 shares
@ $1.97, valued at
$2M
|
|
| 04/04/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/15/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 01/10/2023 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 5.2% stake in Cocrystal Pharma, Inc. |
| 01/09/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/26/2022 |
8-K
| Quarterly results |
| 10/03/2022 |
8-K
| Quarterly results |
| 09/12/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/03/2022 |
4
| Japour Anthony J (Director) has filed a Form 4 on Cocrystal Pharma, Inc.|
Txns:
| Granted 148,000 options to buy
@ $0.42, valued at
$62.2k
|
|
| 08/03/2022 |
4
| Martin James Joseph (Co- Interim CEO and CFO) has filed a Form 4 on Cocrystal Pharma, Inc.|
Txns:
| Granted 300,000 options to buy
@ $0.42, valued at
$126k
|
|
| 08/03/2022 |
4
| PFENNIGER RICHARD C JR (Director) has filed a Form 4 on Cocrystal Pharma, Inc.|
Txns:
| Granted 80,000 options to buy
@ $0.42, valued at
$33.6k
|
|
| 08/03/2022 |
4
| FROST PHILLIP MD ET AL (Director) has filed a Form 4 on Cocrystal Pharma, Inc.|
Txns:
| Granted 220,000 options to buy
@ $0.42, valued at
$92.4k
|
|
|
|
|